TSRO Share Price

Open 156.32 Change Price %
High 161.72 1 Day 6.38 4.15
Low 154.21 1 Week 7.95 5.23
Close 160.00 1 Month -27.42 -14.63
Volume 997141 1 Year 112.06 233.75
52 Week High 192.94
52 Week Low 36.68
TSRO Important Levels
Resistance 2 166.96
Resistance 1 164.09
Pivot 158.64
Support 1 155.91
Support 2 153.04
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 2
As on 24th Mar 2017 TSRO Share Price closed @ 160.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 109.16 & Sell for SHORT-TERM with Stoploss of 164.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for March
1st Target up-side 207.95
2nd Target up-side 221.68
3rd Target up-side 235.4
1st Target down-side 168.79
2nd Target down-side 155.06
3rd Target down-side 141.34
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
TSRO Latest News
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.